Catheter ablation of atrial fibrillation in heart failure reduces mortality and hospitalization: The CASTLE-AF trialFebruary 20, 2018
Compared with medical therapy alone, catheter ablation of atrial fibrillation in patients with heart failure reduced the risk for all-cause mortality and hospitalization.
Patients with persistent atrial fibrillation who received targeted therapy saw improvements in sinus rhythm as well as reductions in blood pressure, cholesterol, and weight.
A 56-year-old man with improved flu-like symptoms, but marked shortness of breath and palpitations, presents to an urgent care center.
A 45-year-old man presents to the emergency department with some mental confusion and near syncope.
The HeartStart MRx defibrillator may fail at any time, including during repeated shocks while in AED mode.
Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.
An elderly man with hypertension, diabetes and COPD presents to the ED with dyspnea on exertion with a productive cough and chest tightness.
Catheter ablation was associated with a significant reduction in a composite end point of death from any cause or hospitalization for worsening heart failure in patients with atrial fibrillation.
Left bundle branch block is associated with a smaller degree of left ventricular ejection fraction improvement.
Sauna exposure is associated with improvements in cardiovascular function and arterial compliance.
In a recent study, implantable cardioverter-defibrillators treated sustained ventricular arrhythmias, including shocks and antitachycardia.
The International Liaison Committee on Resuscitation released an updated consensus on cardiopulmonary resuscitation and emergency cardiovascular care.
Patients with atrial fibrillation have a higher risk for ischemic stroke compared with patients with atrial flutter.
MRI conducted at a strength of 1.5 Tesla is safe for patients with a legacy pacemaker or implantable cardioverter-defibrillator system.
Early ventricular arrhythmias are linked to significantly reduced survival for patients post contemporary continuous flow left ventricular assist device implantation.
Uninterrupted and minimally interrupted apixaban are associated with low rates of thromboembolic events in patients undergoing catheter ablation for nonvalvular afib.
Current evidence is inadequate to assess benefits and harms of ECG screening for atrial fibrillation.
The burden of ventricular tachycardia can be reduced with noninvasive mapping of cardiac arrhythmias and noninvasive delivery of ablative radiation
Hydroquinidine treatment reduces life-threatening arrhythmic events in short QT syndrome.
Bleeding Risk, Stroke Outcomes With Edoxaban vs Enoxaparin-Warfarin for Cardioversion of Atrial FibrillationDecember 15, 2017
In patients with atrial fibrillation at high risk for stroke, edoxaban is associated with lower rates of cardiovascular death events.
Guidelines for Point-of-Care Use of Transesophageal Echocardiography in Cardiac Arrest ResuscitationDecember 11, 2017
Transesophageal echocardiography offers many clinical benefits in patients with cardiac arrest compared with transthoracic echocardiography.
Patients who had short-run atrial tachyarrhythmia experienced significantly higher rates of stroke compared with patients who did not have short-run atrial tachyarrhythmia.
In patients with new-onset atrial fibrillation, cardiologist care is associated with lower rates of death.
Patients with atrial fibrillation who are treated with oral anticoagulants often experience renal function decline.
The chemical stability of warfarin sodium tablets is not affected by repackaging into dose administration aids.
No significant association was found between atrial fibrillation risk and leukocyte telomere length.
FDA has cleared the KardiaBand device to recordtheir EKG to detect normal heart rhythms and atrial fibrillation.
Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus StatementDecember 05, 2017
A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.
Heart rate variability can differentiate major depressive disorder from depression in bipolar disorder.
The American College of Cardiology released an expert consensus decision pathway intended to guide clinicians in managing bleeding in patients treated with anticoagulation.
The Cardiology Advisor Articles
- A 45-Year-Old Man Presents to the ED With Shortness of Breath, Confusion
- A 56-Year-Old Man With Flu-Like Symptoms Presents With Palpitations
- Acute Coronary Syndrome Benefits From Both Antiplatelets and DOACs
- 6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH
- Fear of E-Cigarette Harm Cuts Teenagers' Use
- Clopidogrel Tablets Recalled Due to Mislabeling
- Mandatory Screening for Congenital Heart Disease: Effects on Infant Mortality
- Short-Run Atrial Tachyarrhythmia Associated With Increased Stroke Risk
- Effects of High-Intensity Exercise Training in Previously Sedentary Adults
- ACC Releases Decision Pathway on Heart Failure With Reduced Ejection Fraction
- Clinical Challenge: Upper Respiratory Infection 1 Year After Heart Transplant
- Use of Multiple Antihypertensive Agents Has Increased in Hospitalizations Complicated by Preeclampsia
- Targeting Underlying Conditions May Improve Sinus Rhythm in Atrial Fibrillation
- Metformin May Preserve Beta-Cell Function in T2DM
- A 67-Year-Old Man With Shortness of Breath After the Sonoma-Napa Wildfires